| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rodrigo A Bressan, Kjell Erlandsson, James M Stone, Rachel S Mulligan, John H Krystal, Peter J Ell, Lyn S Pilowsk. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biological psychiatry. vol 58. issue 1. 2005-09-02. PMID:15992521. |
we used [123i]cns-1261 to determine whether binding to the nmda receptor intrachannel pcp/mk-801 site is affected by schizophrenia or by treatment with typical antipsychotics and clozapine in vivo. |
2005-09-02 |
2023-08-12 |
Not clear |
| Jose de Leon, Francisco J Diaz, Richard C Josiassen, Thomas B Cooper, George M Simpso. Does clozapine decrease smoking? Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 5. 2005-08-26. PMID:15951089. |
smoking and therapeutic response to clozapine in patients with schizophrenia. |
2005-08-26 |
2023-08-12 |
human |
| Chee H Ng, Siow-Ann Chong, Tim Lambert, Agnes Fan, L Peter Hackett, Rathi Mahendran, Mythily Subramaniam, Isaac Schweitze. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International clinical psychopharmacology. vol 20. issue 3. 2005-08-02. PMID:15812267. |
the present study investigated clozapine dosage, plasma clozapine and metabolite levels, clinical and side-effect profiles in asian versus caucasian patients with chronic schizophrenia who were on stable maintenance treatment. |
2005-08-02 |
2023-08-12 |
Not clear |
| Eila Repo-Tiihonen, Anne Eloranta, Tero Hallikainen, Jari Tiihone. Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychobiology. vol 51. issue 4. 2005-07-29. PMID:15870506. |
selective serotonin reuptake inhibitor antidepressants have been considered safe in schizophrenia but in combination with clozapine, that is widely used in chronic treatment-resistant schizophrenia, remarkable pharmacokinetic interactions can occur causing an elevation in clozapine plasma levels. |
2005-07-29 |
2023-08-12 |
Not clear |
| Alex Hofer, Martina Hummer, Georg Kemmler, Martin Kurz, Ilsemarie Kurzthaler, W Wolfgang Fleischhacke. The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 3. 2005-07-18. PMID:12974985. |
the safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. |
2005-07-18 |
2023-08-12 |
Not clear |
| Alex Hofer, Martina Hummer, Georg Kemmler, Martin Kurz, Ilsemarie Kurzthaler, W Wolfgang Fleischhacke. The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 3. 2005-07-18. PMID:12974985. |
in addition to its established superiority over other antipsychotics in treatment-resistant patients, clozapine has been consistently shown to improve psychopathology and other psychosocial outcome variables in patients with schizophrenia. |
2005-07-18 |
2023-08-12 |
Not clear |
| Mario Rodrigues Louzã, Debora Pastore Bassit. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up. Journal of clinical psychopharmacology. vol 25. issue 2. 2005-07-15. PMID:15738751. |
seven patients meeting diagnostic and statistical manual of mental disorders, revised third edition criteria for chronic exacerbated schizophrenia (mean age 28.5 +/- 10.2 years) and presenting severe td, defined as abnormal involuntary movements scale score above 13, were treated with clozapine and followed up for 5 years. |
2005-07-15 |
2023-08-12 |
Not clear |
| Vicente Molina, Juan D Gispert, Santiago Reig, Javier Sanz, Javier Pascau, Andrés Santos, Manuel Desco, Tomás Palom. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology. vol 178. issue 1. 2005-07-14. PMID:15365682. |
cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. |
2005-07-14 |
2023-08-12 |
Not clear |
| Leslie Citrome, Robert M Bilder, Jan Volavk. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. Journal of psychiatric practice. vol 8. issue 4. 2005-07-13. PMID:15985880. |
clozapine was the first antipsychotic medication to be approved for the indication of treatment-refractory schizophrenia. |
2005-07-13 |
2023-08-12 |
Not clear |
| Nii A Addy, Ana Pocivavsek, Edward D Levi. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 6. 2005-07-11. PMID:15688087. |
therapeutic treatment with clozapine in people with malfunctions of the hippocampus such as seen in schizophrenia may improve cognitive performance, whereas the same doses of clozapine may impair memory in individuals without hippocampal malfunction. |
2005-07-11 |
2023-08-12 |
rat |
| Claire Advoka. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain. Essential psychopharmacology. vol 6. issue 2. 2005-07-11. PMID:15765792. |
the first atypical antipsychotic, clozapine (clozaril), dramatically improved the outcome of treatment of patients with schizophrenia in two ways. |
2005-07-11 |
2023-08-12 |
Not clear |
| Peter M Wehmeier, Stefan Gebhardt, Jörg Schmidtke, Helmut Remschmidt, Johannes Hebebrand, Frank M Theise. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry research. vol 133. issue 2-3. 2005-06-30. PMID:15741002. |
clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. |
2005-06-30 |
2023-08-12 |
Not clear |
| Peter M Wehmeier, Stefan Gebhardt, Jörg Schmidtke, Helmut Remschmidt, Johannes Hebebrand, Frank M Theise. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry research. vol 133. issue 2-3. 2005-06-30. PMID:15741002. |
here we report on a pair of female monozygotic twins concordant for schizophrenia and mild mental retardation who were treated with clozapine over 5.5 years. |
2005-06-30 |
2023-08-12 |
Not clear |
| A Kalyoncu, H Mirsal, O Pektas, N Unsalan, D Tan, M Beyazyüre. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? Journal of psychopharmacology (Oxford, England). vol 19. issue 3. 2005-06-27. PMID:15888516. |
use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? |
2005-06-27 |
2023-08-12 |
Not clear |
| A Kalyoncu, H Mirsal, O Pektas, N Unsalan, D Tan, M Beyazyüre. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? Journal of psychopharmacology (Oxford, England). vol 19. issue 3. 2005-06-27. PMID:15888516. |
although case reports exist concerning the positive impact of lamotrigine addition on clozapine treatment in resistant schizophrenia, a review of the literature fails to document any evidence regarding a combination of the two in the treatment of patients with schizophrenia and comorbid alcohol dependence. |
2005-06-27 |
2023-08-12 |
Not clear |
| A Kalyoncu, H Mirsal, O Pektas, N Unsalan, D Tan, M Beyazyüre. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? Journal of psychopharmacology (Oxford, England). vol 19. issue 3. 2005-06-27. PMID:15888516. |
in the present study, we present three cases in which patients with resistant schizophrenia and comorbid alcohol use disorder were given lamotrigine to augment clozapine. |
2005-06-27 |
2023-08-12 |
Not clear |
| A Kalyoncu, H Mirsal, O Pektas, N Unsalan, D Tan, M Beyazyüre. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? Journal of psychopharmacology (Oxford, England). vol 19. issue 3. 2005-06-27. PMID:15888516. |
our findings suggest that clozapine plus lamotrigine may be helpful in reducing alcohol consumption and craving among patients with schizophrenia and comorbid alcohol dependence. |
2005-06-27 |
2023-08-12 |
Not clear |
| Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilo. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological psychiatry. vol 57. issue 6. 2005-06-20. PMID:15780844. |
studies performed with taiwanese patients indicate that d-serine significantly improves schizophrenia symptoms when used as adjuvant to conventional neuroleptics but not to clozapine. |
2005-06-20 |
2023-08-12 |
Not clear |
| Susan R McGurk, Cameron Carter, Robert Goldman, Michael F Green, Stephen R Marder, Haiyi Xie, Nina R Schooler, John M Kan. The effects of clozapine and risperidone on spatial working memory in schizophrenia. The American journal of psychiatry. vol 162. issue 5. 2005-06-08. PMID:15863811. |
the effects of clozapine and risperidone on spatial working memory in schizophrenia. |
2005-06-08 |
2023-08-12 |
Not clear |
| Susan R McGurk, Cameron Carter, Robert Goldman, Michael F Green, Stephen R Marder, Haiyi Xie, Nina R Schooler, John M Kan. The effects of clozapine and risperidone on spatial working memory in schizophrenia. The American journal of psychiatry. vol 162. issue 5. 2005-06-08. PMID:15863811. |
the purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia. |
2005-06-08 |
2023-08-12 |
Not clear |